Andrew J. Stewart
CIK 1974516 · View on SEC EDGAR ↗
First SEC filing: Feb. 28, 2025 · Latest: Feb. 28, 2025
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 5, 2026 | BLCO | A | 16,778 | — | — | 103,211 Direct | +19.41% | Acquired | (price as of 2026-08-21) |
| April 24, 2025 | BLCO | F | 3,954 | $13.89 | $54,921 | 62,930 Direct | -5.91% | Disposed | 24.0% (price as of 2026-08-21) |
| Feb. 26, 2025 | BLCO | A | 55,793 | — | — | 55,793 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 26, 2025 | BLCO | A | 23,423 | — | — | 66,884 Direct | +53.89% | Acquired | (price as of 2026-08-21) |
| Dec. 23, 2024 | BLCO | F | 2,524 | $17.83 | $45,003 | 43,461 Direct | -5.49% | Disposed | -3.4% (price as of 2026-08-21) |
| April 24, 2024 | BLCO | F | 3,943 | $14.90 | $58,751 | 45,985 Direct | -7.90% | Disposed | 15.6% (price as of 2026-08-21) |
| Feb. 28, 2024 | BLCO | A | 50,813 | — | — | 50,813 Direct | — | Acquired | (price as of 2026-08-21) |
| Feb. 28, 2024 | BLCO | A | 16,778 | — | — | 49,928 Direct | +50.61% | Acquired | (price as of 2026-08-21) |
| April 24, 2023 | BLCO | A | 33,150 | — | — | 33,150 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 26, 2025 | BLCO | Non-Qualified Stock Options (right to purchase) | Common Shares, No Par Value (55,793) | $15.86 | — | 55,793 | Acquired |
| Feb. 28, 2024 | BLCO | Non-Qualified Stock Options (right to purchase) | Common Shares, No Par Value (50,813) | $16.85 | — | 50,813 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
BLCO
President, Global Pharmaceuticals and International Consumer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $629,077 | — | — | — | $604,800 | — | $15,750 | $2,500,253 |
| 2024 | $616,269 | — | — | — | $552,762 | — | $26,525 | $4,082,270 |
| 2023 | $415,385 | $600,000 | — | — | $344,653 | — | $9,346 | $1,933,266 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.